Latest VIVIS LOI Potential First Step to Phase 1 Clinical Trial on Preventing COVID-19 Infections Using CBD

Rhea-AI Summary

Neutra Corp. subsidiary VIVIS has signed a letter of intent with Mercury Clinical Research for a potential Phase 1 clinical trial to test hemp-based cannabinoids in treating COVID-19. This collaboration aims to explore the efficacy of CBD against SARS-CoV-2, with additional investigations into its potential benefits for inflammation, insomnia, appetite regulation, pain management, and anxiety. The CEO emphasized the significant global impact this research could have, especially given the ongoing pandemic, which has claimed nearly 4.6 million lives worldwide.

Positive

• Signing of a letter of intent for potential Phase 1 clinical trial on CBD efficacy against COVID-19.
• Exploration of multiple therapeutic applications of hemp-based cannabinoids.
• CEO highlights significant global impact potential of hemp-based CBD in addressing COVID-19.

Negative

• None.

KATY, TX / ACCESSWIRE / September 13, 2021 / Neutra Corp. subsidiary VIVIS has signed a groundbreaking letter of intent (LOI) with a Houston clinical research company that, if it comes to a successful conclusion, would lead to testing hemp-based cannabinoids to treat COVID-19.

Under the LOI's provisions, VIVIS will now determine the feasibility of working with Mercury Clinical Research to start phase 1 clinical trial on CBD efficacies in combating SARS-COVID-2. The trials could also investigate additional uses for anti-inflammation, anti-insomnia, appetite suppressant and stimulant (CBG vs. CBN), recovery, pain-management, anti-anxiety, and other health related diagnosis deemed notable for clinical trials.

"We're about to embark on something that could have a tremendous impact worldwide," said Neutra CEO Sydney Jim. "If we ultimately decide to pursue this clinical research, it would easily be one of the biggest and more important things we've done. Right now, COVID has the world in its grip. It's had a far-reaching negative effect on not only people's health but has also taken a terrible toll on the global economy. We'll be looking at whether hemp-based CBD like that VIVIS produces could help reverse that."

There has already been some study into the subject. A group of medical researchers recently reported that "cannabidiol has potential to prevent and inhibit SARS-CoV-2 infection." The researchers' abstract states that human patients previously taking CBD had "significantly lower SARS-CoV-2 infection incidence" when compared to the general population. Click here for more information with this study

Nearly 4.6 million people worldwide have died from COVID-19 as of Sep. 7, 2021. More than 664,000 of those fatalities have been in the U.S. Almost two-thirds of Americans (206 million) have gotten at least one vaccination dose. However, new variations of the coronavirus have appeared, threatening progress in fighting the illness and leading to new infections.

About Neutra Corp.
Neutra Corp. (OTC PINK:NTRR) is an early-stage research and development company with a focus on bringing modern healthy living solutions to a multibillion-dollar market. Cutting-edge technologies within the nutraceuticals, food, and drug, and environmental purification sectors are creating a new kind of world culture-one where in which consumers are demanding access to products that promote health and stave off potential health dangers. One of the nutraceutical sub-markets is the new thriving hemp-based CBD market, in which the Company intends to participate. For more information, visit the Company's website at http://www.NeutraInc.com.

NOTICE REGARDING FORWARD-LOOKING STATEMENTS
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words 'believes,' 'expects,' 'anticipate' or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.

Neutra Contact:
Sydney Jim
888-433-4033
info@neutrainc.com

SOURCE: Neutra Corp

View source version on accesswire.com:
https://www.accesswire.com/663687/Latest-VIVIS-LOI-Potential-First-Step-to-Phase-1-Clinical-Trial-on-Preventing-COVID-19-Infections-Using-CBD

FAQ

What is the purpose of Neutra Corp.'s recent letter of intent?

The letter of intent aims to explore the feasibility of conducting a Phase 1 clinical trial on using hemp-based cannabinoids to treat COVID-19.

What are the potential benefits of CBD being tested in the clinical trial?

The clinical trial could investigate CBD's efficacy in combating COVID-19 and its effects on inflammation, insomnia, appetite suppression, pain management, and anxiety.

When was the letter of intent signed?

The letter of intent was signed on September 13, 2021.

What is the significance of this clinical trial for Neutra Corp.?

If successful, this trial could be one of the most important initiatives for Neutra Corp., potentially having a tremendous worldwide impact on health and the economy.

How many deaths have been caused by COVID-19 globally?

As of September 7, 2021, nearly 4.6 million people have died due to COVID-19 worldwide.